For the quarter ending 2026-03-31, RGEN made $194,255K in revenue. -$3,445K in net income. Net profit margin of -1.77%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 194,255 | 181,500* | 188,805 | 182,366 |
| Cost of goods sold | 85,971 | 82,740* | 88,290 | 91,224 |
| Research and development | 14,458 | 11,978* | 14,175 | 13,958 |
| Selling, general and administrative | 76,536 | 73,173* | 73,663 | 71,227 |
| Restructuring activities and other charges | 1,496 | - | - | - |
| Change in fair value of contingent consideration | -146 | 4,524* | -4,148 | -7,939 |
| Total costs and operating expenses | 178,315 | 172,414* | 171,980 | 168,470 |
| Income from operations | 15,940 | 9,086* | 16,825 | 13,896 |
| Investment income | 6,342 | 7,312* | 6,921 | 6,585 |
| Interest expense | 5,578 | 5,361* | 5,414 | 5,354 |
| Loss on extinguishment of debt | - | 0* | - | - |
| Amortization of debt issuance costs | 419 | 412* | 416 | - |
| Loss on sale of business | -13,763 | - | - | - |
| Amortization of debt issuance costs | - | - | - | 414 |
| Other expense, net | -750 | -1,232* | -804 | 3,502 |
| Other (expense) income, net | -14,168 | 307* | 287 | 4,319 |
| Income before income taxes | 1,772 | 9,393* | 17,112 | 18,215 |
| Income tax (benefit) provision | -6,561 | 5,164* | 2,201 | 3,349 |
| Net income | 8,333 | 4,229* | 14,911 | 14,866 |
| Unrealized loss on available-for-sale securities, net of tax | -113 | 13* | - | - |
| Foreign currency translation adjustment | -11,665 | -15,612* | -2,391 | 46,125 |
| Comprehensive (gain) income | -3,445 | -11,370 | 12,520 | 60,991 |
| Basic EPS | 0.15 | -202.311 | 0.27 | 0.26 |
| Diluted EPS | 0.15 | -200.747 | 0.26 | 0.26 |
| Basic Average Shares | 56,354,000 | 56,203 | 56,265 | 56,234 |
| Diluted Average Shares | 56,666,000 | 56,641 | 56,532 | 56,510 |
REPLIGEN CORP (RGEN)
REPLIGEN CORP (RGEN)